Table 1.
Corresponding FGF/FGFR account for resistance to therapy in cancers
| Cancer types | Therapeutic method | Invovled FGF/FGFR |
|---|---|---|
| Lung cancer | Erlotinib | FGF13, FGFR1/2/3 |
| Gefitinib | FGF2/9, FGFR1/2/3 | |
| Afatinib | FGFR1 | |
| Trametinib | FGFR1 | |
| Palbociclib | FGFR1 | |
| Cisplatin | FGF2 | |
| Breast cancer | Tamoxifen | FGF1/2/4, FGFR1 |
| Fulvestrant | FGF1/2/4, FGFR1 | |
| Pictilisib | FGF2 | |
| Everolimus | FGF2 | |
| Bevacizumab | FGF2 | |
| Doxorubicin | FGF2, FGFR4 | |
| Cyclophosphamide | FGFR4 | |
| Colorectal cancer | radiotherapy | FGFR4 |
| 5-Fu | FGFR4 | |
| Oxaliplatin | FGFR4 | |
| 5-Fu+radiotherapy | FGFR2 | |
| Gastrointestinal stromal tumor | Imatinib | FGF2, FGFR1/3 |
| Squamous cell carcinoma | Radiotherapy | FGF2, FGFR3 |
| Bevacizumab | FGF2 | |
| Paclitaxel | FGF2 | |
| Lapatinib | FGF1/7/10 | |
| Osteosarcoma | Cisplatin | FGF2 |
| Hepatocellular carcinoma | Gefitinib | FGF8 |
| Sorafenib | FGFR1 | |
| Pancreatic tumors | Antiangiogenic therapy | FGF2 |
| Melanoma | Temozolomide | FGF2 |
| PLX51107 | FGF2 | |
| Chronic lymphocytic leukemia | Fludarabine | FGF2 |
| Myeloma | Dexamethasone | FGFR3 |
| Urothelial cancer | Gemcitabine | FGFR3 |
| Adriamycin | FGFR3 | |
| Prostate cancer | Castration | FGF8 |
CDK4 inhibitor: Palbociclib; Antiestrogens: Tamoxifen, Fulvestrant; PI3K inhibitor: Pictilisib; mTOR inhibitor: Everolimus; BET inhibitor: PLX51107.